My journey to Seville, where tomorrow’s sunflowers grow

Anyone who has ever stood beside a sunflower knows the quiet astonishment of being matched, petal for head, by a flower. Now imagine weaving your way through tens of thousands of stems at eye level, each one tethered to the transparent ceiling by a white cord, as if suspended between earth and sky. Overhead stretches a vision in perfect symmetry: thousands of threads rising in parallel, anchoring a forest of blossoms veiled like brides at the altar, their vivid yellow only just shimmering through the gauze. It could be a contemporary art installation, but this is the greenhouse of the world’s most advanced sunflower research center. We are not at the Venice Biennale nor at Documenta in Kassel, but just outside Seville, at the Centro Tecnológico de Investigación de La Rinconada.

Continue reading

Genetic rescues for biodiversity? Proceed with caution

Photo©IUCN/Andrew McConnell/Workers Photos

The International Union for Conservation of Nature (IUCN) rejects the moratorium request and approves a resolution recognizing the risks and benefits of SynBio techniques, calling for case-by-case evaluations

Continue reading

Can you afford a CRISPR cure?

As you probably know, Alta Charo is one of the most influential (and nice) bioethicists on the international scene. In this video, she explains why gene therapies are “a medical miracle and an economic disaster,” before broadening the focus to more general issues such as the tensions between individual, professional, and collective ethics.

Beyond Baby KJ: manufacturing lessons for the next CRISPR cures

The coordinated effort that last spring saved the life of little KJ Muldoon earned widespread and enthusiastic media coverage. But between the invention of the treatment and its delivery to the patient lay a lesser-told story: an unprecedented manufacturing sprint. Genetic Engineering & Biotechnology News organized an online roundtable led by its deputy editor in chief, Julianna LeMieux, to discuss how therapeutic components were produced quickly, cost-effectively, and to clinical-grade standards.

Continue reading

The US against RNA: how did it end? 

Last spring, we reported on the possible fall from grace of messenger RNA technology within the US administration. This was despite the Nobel Prize awarded to Katalin Karikó and Drew Weissman, and despite the millions of lives saved by RNA vaccines during the COVID-19 pandemic. So, how did it end? 

Continue reading

CRISPR-GPT: a copilot for editing

Nature Biomedical Engineering has introduced a chatbot specifically designed to help beginners with their first experiments and to support experienced researchers in their work.

Since it was first described in Science in 2012, in the landmark paper by Emmanuelle Charpentier and Jennifer Doudna, the success of the CRISPR technique has been summed up with a handful of adjectives: cheap, precise, easy to use. But since everything is relative, it’s worth asking: how easy, and compared to what? When measured against previous genetic editing platforms, CRISPR is far simpler to apply. Whereas only a few highly specialized centers could once perform these experiments, with CRISPR a standard lab, the basic skills of an ordinary biologist, and solid familiarity with bioinformatics may be enough. Still, novices need guidance, and even seasoned researchers can run into problems.

Continue reading

CRISPR news from the world

A selection of news we missed during August. Reuters reports on the controversy surrounding horses edited by Kheiron Biotech to enhance their muscles. In Argentina, veterinary reproductive technologies are cutting-edge, and the use of cloning in horse breeding is accepted. Still, for now, genetically edited animals are not allowed to compete in polo.

Continue reading

CRISPR cures for kids? A new center is born!

Jennifer Doudna and Priscilla Chan

Last May, the case of baby KJ made headlines: the child, suffering from a severe metabolic disorder, received a therapy developed specifically for him in just six months. The rapid improvement in his condition and his discharge from the hospital left the rare disease community with a pressing question: was this an unrepeatable one-off, or a replicable model of intervention? The right answer might be the latter, as demonstrated by the launch of the Center for Pediatric CRISPR Cures in California. This new center, to be led by Fyodor Urnov, begins with the mission of developing customized genome-editing treatments for eight young patients with congenital metabolic and immune system disorders.

Continue reading